Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies
- 27 April 2011
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 30 (10) , 1333-1339
Abstract
Autoantibodies to topoisomerase I (topo I), RNA polymerase III (RNAPIII), centromere, U3RNP/fibrillarin, Th, PM-Scl, and U1RNP found in scleroderma (SSc) are associated with unique clinical subsets. The effects of race and gender on autoantibody prevalence and clinical manifestations were examined. Autoantibodies in sera from 105 SSc (include 75 Caucasian, 24 African-American, 6 others; 89 females and 16 males) were analyzed by immunofluorescence and immunoprecipitation. Clinical information was from database. SSc-related autoantibodies seldom coexist except for anti-topo I and anti-U1RNP. Anti-topo I (35% vs 15%), anti-U3RNP (30% vs 3%, p = 0.0005), and anti-U1RNP (30% vs 13%) were more common in African-Americans vs Caucasians. Anti-centromere (17%) and anti-PM-Scl (only in 8% of female) were found only in Caucasians. In race/gender combination, all three African-American males had anti-topo I (p = 0.04). Anti-U3RNP (35% vs 3%, p = 0.0005) and anti-U1RNP were common in African-American females. In African-American, all nucleolar dominant staining sera had anti-U3RNP; nuclear pattern was topo I (50%), U1RNP (19%), and RNAPIII (13%). In Caucasian, nucleolar was anti-Th (43%) and PM-Scl (29%); nuclear pattern was RNAPIII (29%), topo I (24%), and U1RNP (18%). Anti-topo I, anti-RNAPIII, and anti-U3RNP were associated with diffuse SSc while anti-centromere, anti-Th, and anti-U1 with limited disease. Proximal scleroderma was less common in African-American with anti-topo I (38% vs 91% in Caucasian, p = 0.04). The production of SSc-related autoantibodies is gender and race dependent, and this can be highly relevant in understanding their clinical significance.Keywords
This publication has 31 references indexed in Scilit:
- Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with SclerodermaThe Journal of Rheumatology, 2010
- Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in ItalyThe Journal of Rheumatology, 2009
- Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progressionAutoimmunity Reviews, 2009
- Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence patternRheumatology, 2009
- Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseasesModern Rheumatology, 2009
- Nucleolar staining cannot be used as a screening test for the scleroderma marker anti–RNA polymerase I/III antibodiesArthritis & Rheumatism, 2006
- Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritisClinical Rheumatology, 2006
- Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.Journal of Clinical Investigation, 1994
- Autoantibody to U3 Nucleolar Ribonucleoprotein (Fibrillarin) In Patients with Systemic SclerosisArthritis & Rheumatism, 1992
- Scl 70 antibody—a specific marker of systemic sclerosisBritish Journal of Dermatology, 1986